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Varicose Veins: Loss of Release of Vascular Endothelial Growth Factor
and Reduced Plasma Nitric Oxide
S. J. Hollingsworth∗, C. B. Tang, M. Dialynas and S. G. E. Barker
The Academic Vascular Unit, Department of Surgery, The Royal Free and University College London Medical School,
The Middlesex Hospital, Mortimer Street, London W1N 8AA
Objectives: to examine the release of vascular endothelial growth factor (VEGF) and nitric oxide (NO) in primary
varicose veins (VVs) and normal vein controls following experimentally-induced venous stasis.
Design, materials and methods: patients with primary VVs (n=21) and control subjects (n=11) were rested supine
for 15 min. Blood was collected from both an arm and foot vein. A below-knee cuff was applied and inflated to 90–95 mmHg
for 10 min (to prompt venous stasis). Further blood samples were collected from the foot vein. Levels of plasma VEGF
and NO were analysed.
Results: in control subjects, application of the cuff increased levels of plasma VEGF in the foot (p<0.025). In contrast,
in patients with VVs, there was little or no change in these levels of plasma VEGF. Cuff application had little effect on
levels of plasma NO in either controls, or those with VVs. When compared to controls however, the levels of plasma NO
in all samples with VVs (arm, or foot before, or after, cuff application) were reduced (all, p<0.05).
Conclusions: loss of VEGF release with experimentally-induced venous stasis, and reduced levels of plasma NO may
suggest a mechanism important in the development of primary VVs.
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Introduction These effects and responses, combined with the basic
changes in blood chemistry, will undoubtedly off-set
Changes in the flow, or chemistry, of blood within the homeostatic balance found normally within the
vessel wall. Here, the appropriate response shouldveins and arteries may lead to a temporary hypo-, or
hyper-tensive intra-luminal state, to which the normal be to mediate dilatation and/or, increase vessel wall
permeability. A continued stimulus to induce dilationphysiological response should be vessel wall con-
striction, or dilatation respectively. Thus, a reduction however, may predispose, initiate, or help contribute
towards the development of primary varicose veinsin venous return, perhaps due to reduced ‘‘calf muscle
pump’’ action (as may be apparent with prolonged (VVs).
Central to maintaining vessel wall reactivity muststanding), might lead therefore, to increased venous
filling and subsequently, to a rise in intra-luminal the production and release of agents mediating con-
striction and dilatory responses. As yet, it is unclearvenous pressure within the veins of the legs.1,2 The
resultant venous stasis, relative hypoxia, reduction in whether the development of varicosity results more
from a central defect in the balance between thesepH3–5 and associated increase in oxidative metabolites
and reactive oxygen species, if not relieved, may all agents, or whether there is a different underlying
pathology that ultimately renders VVs unable to me-be damaging to the vessel wall.6–9 The sequelae from
the presence of these factors, for example, the release diate these responses appropriately. Perhaps, the con-
tinued stimulation to dilate, with the vessel wallof pro-inflammatory cytokines due to the activation
of monocytes,10 macrophages11 or neutrophils2,6 would responding appropriately to the changes in luminal
pressure and/or chemistry, leads ultimately to thelikely, further exacerbate the damaging process(es).
pathology seen in primary VVs? It is important there-
fore, to understand whether primary VVs retain the
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responsible for mediating constriction and dilatation. Human Research. Patients attending the Vascular Unit,
The Middlesex Hospital, London for assessment forAlthough various reports have examined the ability
of normal and VVs to contract12–15 and relax,13,15 these primary VVs and normal subjects from those within
the Department of Surgery were asked to participatestudies have been performed primarily on ‘‘ring’’ sec-
tions of veins investigated pharmacologically in organ and then, consented. (All individuals enrolled in this
study were non-smokers and receiving no med-bath studies. Furthermore, these studies have ex-
amined the ability of the vein to respond to agents ications.)
mediating constriction and dilatation when added exo-
genously, and not the ability of the vein to produce
these agents under the more natural stimulus of, for
Induction of venous stasisexample, venous stasis.
Previously, Mangiafico and co-workers (1997) ex-
Control subjects (with ‘‘normal’’ veins; n=11), oramined the release of endothelin-1 (ET-1 – a major
patients with primary VVs (as confirmed by venousconstrictor agent of arteries and veins) in normal and
Duplex ultrasound scanning; n=21) were rested su-VVs.16 Control subjects and patients with primary VVs
pine. Using a G23 butterfly, a pronounced foot veinwere rested supine for 30 min, following which a
was cannulated and then flushed through with 5 mlsphygmomanometer cuff was used (keeping the pres-
of saline for injection. Control subjects and patientssure in the cuff intermediate between the systolic and
then continued to rest supine for a further 10 min.diastolic blood pressures) to induce a relative venous
Subsequently, 5 ml of peripheral blood was collectedstasis for 10 min. Comparisons were then made (using
(into EDTA; Vacutainer) from the foot vein (followedradio-immunoassay) between the levels of plasma ET-
by a 5 ml flush of saline for injection) and 10 ml from1 before and after cuff application. In patients with
an arm vein. Whilst remaining supine, a sphygmo-primary VVs, the plasma levels of ET-1 were elevated
manometer cuff was placed directly below the kneesignificantly compared to controls. Furthermore, al-
and inflated to 90–95 mmHg for 10 min. A further 5 mlthough both controls and patients with primary VVs
of peripheral blood was then obtained from the footdemonstrated a significant increase in the levels of
vein (as before).plasma ET-1 after application of the cuff, the absolute
Within 15 min of collection, samples of peripheralincrease in plasma ET-1 was significantly greater in
blood were separated through Ficoll (400 g for 25 min;VVs than in controls. Given this clear ability to release
brake off) and the plasma removed and transferred toET-1, why therefore, do VVs appear and/or remain
CryoVials (Nunc, U.K.) and stored at −20 °C untildilated?
analysed. The levels of plasma VEGF and NO wereAlthough the reduced contraction to ET-1 in VVs in
determined using commercially available kits (as de-vitro may be associated with a decrease in the number
tailed below).of endothelin-B subtype receptors,14 a partial loss of
contraction in VVs could not explain entirely, the
continued dilatation seen. Do therefore, VVs reflect an
imbalance between contraction and dilatation which
Analysis of levels of plasma VEGFis mediated not only by loss of ability to contract, but
also and perhaps more significantly, an aberrant or
Levels of plasma VEGF were determined using ancontinued stimulus to dilate? To date, little is known
indirect ELISA assay kit (R&D Sytems, U.K.) andas to the ability of VVs to produce and release those
according to the manufacturer’s instructions. (Allagents responsible for mediating dilatation. Vascular
reagents, unless specified, were supplied by R&Dendothelial growth factor (VEGF) plays a central role
Systems (U.K.); TWEEN, PBS, TBS, BSA, sucrose,in maintaining vascular reactivity and integrity, which,
carbonate and bicarbonate were purchased from Sigmain concert with nitric oxide (NO), mediates vaso-per-
(U.K.)). Briefly, 96-well, flat-bottomed Maxisorb mi-meability and dilatory responses.17–19 Our aim here
cro-titre plates (Nunc, U.K.) were pre-coated overnighttherefore, was to examine the ability of primary VVs
(at 4°C) with capture antibody (0.4 g/ml goat anti-to release VEGF and NO in response to an induced
human VEGF polyclonal; AF-293-NA) in carbonate/venous stasis.
bicarbonate buffer (each 0.05 M, pH 9.6). Antibody
solution was discarded and the plates washed threeMethods
times with wash buffer (0.05% TWEEN in PBS). Wells
were blocked for 2 h (room temperature) with blockingThis study was conducted following approval from
the Joint UCL/UCLH Committees on the Ethics of buffer (1% BSA, 5% sucrose in PBS) and then washed
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(×3, as described above). Plasma samples, or stand- Standard curves were created for each experiment
and for analysis, the mean of two experiments, eachards (7.8–4000 pg/ml human recombinant VEGF165;
293-VE-010), diluted 1:1 in diluent (0.1% BSA, 0.05% with duplicate wells/standard or sample, were cal-
culated and used for further analysis.TWEEN in PBS), were added and incubated for 2 h
(at room temperature). Samples were discarded and
the plates washed (×3, as before). Detection antibody
(0.2 g/ml biotinylated goat anti-human VEGF poly-
Statisticsclonal; BAF293), in diluent (as above), was added for
2 h (at room temperature) and then, plates washed
The experimentally obtained results were of a normal(×3, as before). Extravidin, conjugated to alkaline-
distribution as determined by a one-sample Kol-phosphatase (Sigma, UK), diluted 1:50 000 in diluent
mogorov–Smirnov test for normality and have been(as above), was added for 30 min (at room tem-
presented as mean values with 95% confidence in-perature), plates washed (×3, as above) and substrate
tervals (95% CI) in parentheses. Accordingly, com-(1 p-nitrophenyl phosphate tablet [pNPP; Sigma Fast⊂]
parison of results before and after cuff applicationadded to 1 tablet TBS in de-ionised water), made fresh
were made using the Student’s t-test for paired results,and used within 15 min, added. Plates were incubated
whilst between controls and experimental groups,in a dark chamber for 60 min (at room temperature)
comparison was made using the Student’s t-test forbefore reading their optical density (OD) at 405 nm
unpaired results. All tests were two-tailed.(Dynex microplate reader).
Standard curves (of 7.8–4000 pg/ml recombinant
human VEGF in doubling dilution) were created for
each experiment (duplicate wells/concentration). For Results
analysis of samples, the mean of three experiments
(each with duplicate wells/sample) was calculated Twenty-one patients with primary VVs were enrolled
and then used for further analysis. into the study (6 men and 15 women; median age, 46
(range, 21–78) years) and 11 control subjects (7 men
and 4 women; median age, 32 (range, 22–55) years).
Analysis of levels of plasma NO
Levels of plasma NO were determined by Greiss Re- Release of plasma VEGF
agent (R&D Systems, U.K.) and according to the manu-
facturer’s instructions; the assay has been designed to The analysis of the levels of plasma VEGF proved
variable dependent on the quality of the sample ob-measure levels of ‘‘total nitrites’’ (NO2−); all reagents,
unless specified, were as provided by the manu- tained; for example, where blood samples obtained
were limited in volume, or had coagulated to somefacturer. Briefly, samples were diluted 1:1 in reaction
buffer (1×, diluted from 10× stock) and then to degree, both of which occurred associated with the
difficulty in obtaining blood from the foot veins ofeliminate proteins, ultra-filtered through a 10 000 MW
cut-off filter (Millipore, U.K.). Samples, or standards some individuals. Hence, samples from individuals
were included for analysis here, only if they produced(sodium nitrate, 3.125–100 mol/L in doubling di-
lution), were added to the wells of a 96-well microtitre on (three) consecutive and separate analyses by ELISA,
results with less than a 10% inter-experimental vari-plate (as provided) and mixed 1:1 with reaction buffer
(total volume, 100 l). Next, 25 l NADH (beta-nicotin- ation. The results are summarised in Table 1.
The baseline levels of plasma VEGF from the arm,amide adenine dinucleotide) were added to each
well, followed by 25 l nitrate reductase. The plates or foot after rest but before application of the cuff,
were similar in control subjects, or those with primarywere ‘‘tapped’’ gently to mix the contents of the wells,
covered with adhesive strip, and incubated at 37 °C for VVs, and also, between the two experimental groups
(all, p>0.1; Table 1).30 min. Following incubation, 50 l of Greiss reagent I
(sulfanilamide in 2N hydrochloric acid), and then 50 l In control subjects, following application of the
below-knee cuff for 10 min, there was a clear increaseof Greiss reagent II (N-(1-naphthyl) ethylenediamine
in 2N hydrochloric acid) were added to each well and in the levels of plasma VEGF; an overall increase in
the mean level of plasma VEGF of 8.5 (−3.4–20.3)%the contents mixed by tapping. Next, plates were
incubated for 10 min at room temperature and their (95% CI, p<0.025, Student’s paired t-test; Table 1).
However, in contrast, in those with VVs, applicationOD recorded at 540 nm (Dynex microplate reader).
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Table 1. Levels of plasma VEGF. the levels of NO detected in the plasma were reduced
as compared to the control subjects (all, p<0.05; for arm,Control veins Varicose veins
(ng/ml) (ng/ml) or foot, before or after cuff application; all, Student’s
unpaired t-test; see Table 2).
Arm 6.07 (1.44–10.7) 6.26 (1.59–10.9)
Before cuff 6.10 (1.87–10.3) 6.13 (1.67–10.6)
After cuff 6.67 (2.10–11.2)† 5.93 (2.01–9.84)
∗n 8 12
Discussion
Levels of plasma VEGF (ng/ml) in peripheral blood samples ob-
tained from the arm and foot veins, before and after cuff application,
Characteristically, VVs are dilated and tortuous, havein control subjects and patients with primary VVs. Values are
presented as means with 95% confidence intervals (95% CI) in aberrant smooth muscle cell (SMC) growth and dis-
parenthesis. ∗n, is the number of individuals whose results were tribution and interruption of the layers of smooth
used for analysis, those in whom repeat ELISA analysis produced
muscle by elastin and collagen fibres suggesting col-consecutive results with <10% inter-experimental variation; each
value represents the mean of at least triplicate experiments, each of lectively, an overall loss of the vein walls’ structural
at least duplicate wells per experiment. ‘‘Before cuff’’ and ‘‘after integrity.20–23 However, the contractility and reactivity
cuff’’ are samples obtained from foot veins. †p<0.025, ‘‘before’’
of SMCs taken from VVs is similar to those fromversus ‘‘after’; cuff application, Student’s paired t-test.
normal veins.24 This suggests that the SMC component
Table 2. Levels of plasma NO. of the vein wall at least, should be able to function as
normal. However, the vein wall must also be able to
Control veins Varicose veins
retain its ability to respond appropriately to the stimuli(pmol/L) (pmol/L)
of changes in local physiology, for example, if there is
Arm 46.9 (28.5–65.3) 30.1 (25.2–35.1)§ lowered pH, or reduced oxygenation, the vein wall
Before cuff 47.8 (30.2–65.4) 32.4 (26.7–38.0)§
must primarily, be able to produce and release agentsAfter cuff 48.0 (29.4–66.7) 32.8 (27.3–38.2)§
that mediate dilatation. Similarly, the vein must be∗n 11 20
able to balance these effects, by constricting. Does the
Levels of plasma NO (pmol/L) in peripheral blood samples obtained appearance of VVs reflect a disruption in the balance
from the arm and foot veins, before and after cuff application, in between dilatation and constriction?control subjects and patients with primary VVs. Values are presented
A number of recent studies using isolated ‘‘ring’’as means with 95% confidence intervals (95% CI) in parenthesis.
∗n, is the number of individuals whose results were used for sections of vein and organ bath pharmacology, have
analysis, those in whom levels of plasma NO were determinable; focused on examining the change in response in VVseach value represents the mean of duplicate experiments each of
to agents that stimulate constriction and dilatation.duplicate wells. ‘‘Before cuff’’ and ‘‘after cuff’’ are samples obtained
from foot veins. §p<0.05, ‘‘normal’’ versus ‘‘varicose’’ for all samples Ring sections of VVs have a reduced ability to constrict
(arm, leg before and after), Student’s unpaired t-test. (as judged by the maximal tension induced) in re-
sponse to norepinephrine, angiotensin-II, KCl and en-
of the below-knee cuff had little or no effect on the dothelin-1 (ET-1).12 Furthermore, the ability to constrict
levels of plasma VEGF detected; a change in the overall to these agents was found to be related to the pro-
mean level of plasma VEGF of 4.2 (−15.7–24.1)% gression of varicosity,12 an effect which, for ET-1, may
(Table 1). be associated with a reduction in receptor expression
as regulated at the transcriptional level.14 Similarly,
endothelium-dependent relaxation to calcium iono-
phore and endothelium-independent relaxation toRelease of plasma NO
either NO, or forskalin, was reduced.15
In vivo, the most likely source of those agents me-The results are summarised in Table 2.
As with plasma VEGF, the baseline levels of plasma diating vascular reactivity is from the vein wall itself.
However, to date, studies examining this function inNO from the arm and foot, after rest but before ap-
plication of the cuff, were similar in either the control the walls of VVs have been fairly limited.
Schuller-Petrovic and co-workers (1997) examinedsubject group, or the group with primary VVs (all,
p>0.1; Table 2). In contrast to VEGF however, cuff the plasma of normal individuals and patients with
VVs.13 With VVs, whilst levels of ET-1, cAMP andapplication for 10 min had little or no effect on the
levels of plasma NO detected in either controls of bradykinin were similar, levels of cGMP (the mech-
anism via which relaxation to NO is induced) werethose with primary VVs (all, p>0.1; see Table 2).
Furthermore, and in contrast to the levels of plasma increased and angiotensin-II was reduced. Overall, the
results suggested that ECs from VVs secreted fewerVEGF, in all samples from patients with primary VVs
(from the arm, or foot, before or after cuff application), mediators of constriction, whilst increased cGMP/
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NO favoured dilatation. In separate studies, when In contrast to VEGF, the baseline levels of NO in
examining the release of ET-1 in plasma following patients with VVs were significantly reduced com-
venous stasis (induced by a below-knee cuff), the pared to control subjects (all p<0.05; see Table 2). The
results were contrasting.16 Here, cuff application for basis behind these reduced levels is unclear as, if NO
10 min induced a significant increase in levels of is the primary agent mediating dilatation, then it might
plasma ET-1 in both control subjects and patients with be expected for the levels of plasma NO to be some-
VVs, but the absolute increase in ET-1 was greater what elevated. The age of our subjects might be factor
with VVs. Furthermore, and perhaps of greater import- as those with VVs had a higher median and range of
ance, the baseline levels of plasma ET-1 before cuff age (46 [21–78] years) than the control subjects (32
application were significantly higher with VVs. In- [22–55] years); for reasons as explained above. How-
deed, the reduced response to ET-1 in VVs associated ever, our own experience is that the levels of plasma
with a reduction in ET-1 receptor expression may result NO tend to be elevated in the more elderly, rather
from receptor ‘‘down-regulation’’ in response to an than reduced (unpublished results). Reduced NO may
increased production of ET-1.16 have resulted from a reduction in the activity of (con-
The main agents promoting dilatation are VEGF and stitutive) NO synthase, damage to the endothelium
NO.18,19 More recently, it has been appreciated that the (such that the stimulus for production is not responded
interplay between these two molecules is central not to), or alternatively, to a breakdown in the inter-play
only to dilatation and permeability, but also to the mechanism(s) with VEGF. Indeed, if VEGF functions
overall homeostatic balance of the vessel wall.17 Here, to stimulate, or enhance NO production,17 loss of VEGF
we have used the model of Magiafico and co-workers receptors, or receptor function within the VV wall,
(1997)16 to examine the production and release of VEGF may help to explain the reduced levels seen.
and NO in control subjects, compared to patients with After cuff application, to induce a mild venous
VVs. (In performing this study, both the age and stasis, control subjects demonstrated (within 10 min)
number of control subjects recruited was lower than increased levels of plasma VEGF (p<0.025; see Table
initially desired, due primarily, to the difficulty in 1). Theoretically, with induced stasis, the stimulus
enrolling volunteer individuals on a ‘‘no-fee’’ basis must be for dilatation and additionally, to increase
who were without primary VVs and of an age matched vein wall permeability. Therefore, the response would
to those individuals from the clinic with primary VVs. seem appropriate for the changes in venous blood
However, the results obtained from these subjects were chemistry that would be expected with stasis. How-
consistent and of low variability). ever, there was little, or no associated change in the
The baseline levels of plasma VEGF (from samples release of NO (see Table 2). Why, is unclear, but ittaken from the arm, or foot, before cuff application)
might reflect the short half-life of NO, methodologicalwere similar in patients with VVs and in control
problems, or perhaps, more simply, to an inability tosubjects (see Table 1). Previously, the levels of systemic
detect changes in the very small amounts of NOVEGF have been reported to be elevated with VVs,
required to elicit a dilatory effect. In this respect, asbut however, only in association with skin changes.25
with previous studies, it may have been more bene-The comparatively ‘‘normal’’ availability of VEGF in
ficial to examine changes in cGMP.13the legs veins of individuals with VVs may therefore,
With VVs patients, there was no change in eithersuggest that the apparent problem with venous re-
VEGF, or NO, after cuff application. In comparison toactivity with VVs (here, dilatation), lies more with the
control subjects, the changes in the venous ‘‘en-inability of the vein to respond, rather than its ability
vironment’’ induced by cuff application were in-to produce VEGF. This may reflect more ‘‘physical’’
sufficient to stimulate the response to release VEGFfactors for example, if the vein wall has dilated max-
(and perhaps, NO) and so, cause dilatation. This func-imally (as is often suggested with VVs), it might be
tional loss of release of VEGF, at least to the stimulusconstrained from dilating any further due either to its
induced here, would tend to support the evidencephysical structure, or from its opposition with the
gathered so far from in vitro studies, supporting thesurrounding tissues. Alternatively, this may be at-
notion of a loss of vascular reactivity in VVs.tributable to a more ‘‘molecular’’ underlying mech-
Overall, it might seem that with VVs there areanism such as a reduction in the density, or changes
elevated plasma levels of those agents that stimulate,in the distribution, of VEGF receptors (KDR and flt-1)
or mediate, the responses of dilatation and con-on and within the wall of VVs, or receptor redundancy
striction13,14,16 and yet, there is a relative loss of sensi-subsequent to a repeated stimulus to dilate, as might
tivity to these agents. Consider, that if a vein isbe the case with prolonged standing and the resultant
pooling of venous blood. stimulated by ‘‘environmental’’ factors such as changes
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